Physician profile
Rose Psara
NPI 1881246833
$5,434.27
in general payments reported to CMS, 2019-2025
32 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $410 · 2023: $1,624 · 2024: $1,361 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $735.71 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $672.78 | 2023-2025 | Auvelity |
| Corium, LLC | $570.72 | 2022-2025 | Azstarys |
| Abbvie INC. | $512.91 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $410.34 | 2021-2025 | Caplyta |
| Alkermes, INC. | $402.52 | 2021-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $275.60 | 2024 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $205.48 | 2021 | |
| Tris Pharma INC | $192.29 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Takeda Pharmaceuticals U.S.A., INC. | $153.41 | 2021-2025 | Trintellix |
| Lundbeck LLC | $142.69 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $141.25 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $127.42 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $121.69 | 2023-2024 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $113.09 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.38 | 2025 | |
| Acadia Pharmaceuticals INC | $86.31 | 2022-2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $56.17 | 2022 | |
| Neos Therapeutics, LP | $52.74 | 2022-2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $51.12 | 2022-2025 | Fanapt |
| Harmony Biosciences LLC | $49.65 | 2024 | |
| Bausch Health US, LLC | $47.27 | 2021-2023 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $39.17 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $30.90 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $30.51 | 2021 | |
| Adlon Therapeutics L.P. | $24.91 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.25 | 2021 | |
| Noven Therapeutics, LLC | $18.64 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $17.85 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $16.50 | 2022 | |
| Livanova USA, INC. | $15.51 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Psara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.